Intestinal Proportion of Blautia sp. is Associated with Clinical Stage and Histoprognostic Grade in Patients with Early-Stage Breast Cancer

Nutrition and Cancer

Volumn 69, Issue 2, 2017, Pages 267-275

  Luu, Trang H ^a   Michel, Catherine ^b   Bard, Jean Marie ^a,c   Dravet, François ^c   Nazih, Hassan ^a   Bobin Dubigeon, Christine ^a,c  

^a UNIVERSITÉ DE NANTES   (France)

^b Universite de Nantes   (France)

^c UMR INSERM U892 CNRS 6299   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RNA 16S;

ADULT; AGED; ARTICLE; BACTERIUM; BACTEROIDETES; BIFIDOBACTERIUM; BLAUTIA; BODY MASS; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; CLOSTRIDIUM LEPTUM; CONTROLLED STUDY; CORIOBACTERIACEAE; DNA EXTRACTION; EGGERTHELLA LENTA; ESCHERICHIA; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; FECES MICROFLORA; FIRMICUTES; HUMAN; INTESTINE FLORA; LACTOBACILLALES; LACTONIFACTOR LONGOVIFORMIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; ROSEBURIA INTESTINALIS; SHIGELLA; BREAST TUMOR; CLOSTRIDIALES; FECES; FEMALE; GENETICS; MICROBIOLOGY; MIDDLE AGED; OBESITY; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CLOSTRIDIALES; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MIDDLE AGED; OBESITY; OVERWEIGHT; RNA, RIBOSOMAL, 16S;

EID: 85009739653     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2017.1263750     Document Type: Article

References (63)

1. Hooper LV, and Gordon JI, :Commensal host-bacterial relationships in the gut. Science 292(5519), 1115–1118, 2001.
2. Lepage P, Leclerc MC, Joossens M, Mondot S, Blottière HM, et al.:A metagenomic insight into our gut's microbiome. Gut 62, 146–158, 2013.
3. Cammarota G, Ianiro G, Cianci R, Bibbò, S, Gasbarrini A, et al.:The involvement of gut microbiota in inflammatory bowel disease pathogenesis:Potential for therapy. Pharmacol Ther 149, 191–212, 2015.
4. Flint HJ, Scott KP, Louis P, and Duncan SH, :The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 9, 577–589, 2012.
5. De Theije CG, Wopereis H, Ramadan M, Van Eijndthoven T, Lambert J, et al.:Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun 37, 197–206, 2014.
6. Sekirov I, Russell SL, Antunes M, and Finlay BB, :Gut microbiota in health and disease. Physiol Rev 90(3), 859–904, 2010.
7. Tamim HM, Musallam KM, Al Kadri MF, Boivin JF, and Collet JP, :Antibiotic use and risk of gynecological cancer. Eur J Obstet Gynecol Reprod Biol 159, 388–393, 2011.
8. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, et al.:Antibiotic use in relation to the risk of breast cancer. JAMA 291(7), 827–835, 2004.
9. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al.:The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101(44), 15718–15723, 2004.
10. Reeves GK, Pirie K, Beral V, Green J, Spencer E, et al.:Cancer incidence and mortality in relation to body mass index in the Million Women Study:cohort study. BMJ 335, 1134–1144, 2007.
11. Protani M, Coory M, and Martin JH, :Effect of obesity on survival of women with breast cancer:systematic review and meta-analysis. Breast Cancer Res Treat 123, 627–635, 2010.
12. Walters WA, Xu Z, and Knight R, :Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett 588, 4223–4233, 2014.
13. Heinonen S, Nurmi T, Liukkonen K, Poutanen K, Wähälä, K, et al.:In vitro metabolism of plant lignans:new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 49(7), 3178–3186, 2001.
14. Wang LQ, :Mammalian phytoestrogens:enterodiol and enterolactone. J Chromatogr B 777, 289–309, 2002.
15. Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, and Queipo-Ortuño MI:Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem 24(8), 1415–1422, 2013.
16. Clavel T, Borrmann D, Braune A, Doré J, and Blaut M, :Occurrence and activity of human intestinal bacteria involved in the conversion of dietary lignans. Anaerobe 12, 140–147, 2006.
17. Matthies A, Loh G, Blaut M, and Braune A, :Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal Slackiaisoflavoniconvertens in gnotobiotic rats. J Nutr 142, 40–46, 2012.
18. Clavel T, Lippman R, Gavini F, Doré J, and Blaut M, :Clostridiumsaccharogumiasp. nov. and Lactonifactorlongoviformisgen. nov., sp. nov., two novel human faecal bacteria involved in the conversion of the dietary phytoestrogen secoisolariciresinol diglucoside. Syst Appl Microbiol 30(16–26), 2007.
19. Jin JS, Kakiuchi N, and Hattori M, :Enantioselective oxidation of enterodiol to enterolactone by human intestinal bacteria. Biol Pharm Bull 30(11), 2204–2206, 2007.
20. Goldin BR, :Intestinal microflora:Metabolism of drugs and carcinogens. Ann Med 22, 43–48, 1990.
21. Dabek M, McCrae SI, Stevens VJ, Duncan SH, and Louis P, :Distribution of b-glucosidase and b-glucuronidase activity and of b-glucuronidase genegus in human colonic bacteria. FEMS Microbiol Ecol 66, 487–495, 2008.
22. Nadkarni MA, Martin FE, Jacques NA, and Hunter N, :Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148, 257–266, 2002.
23. Watanabe K, Kodama Y, and Harayama S, :Design and evaluation of PCR primers to amplify bacterial 16S ribosomal DNA fragments used for community fingerprinting. J Microbiol Methods 44, 253–262, 2001.
24. Bacchetti De Gregoris T, Aldred N, Clare AS, and Burgess JG, :Improvement of phylum- and class-specific primers for real-time PCR quantification of bacterial taxa. J Microbiol Methods 86, 351–356, 2011.
25. Guo X, Xia X, Tang R, Zhou J, Zhao H, et al.:Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 47, 367–373, 2008.
26. Heilig HG, Zoetendal EG, Vaughan E, Marteau P, Akkermans AD, et al.:Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl Environ Microbiol 68, 114–123, 2001.
27. Rinttila T, Kassinen A, Malinen E, Krogius L, and Palva A, :Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97, 1166–1177, 2004.
28. Vanhoutte T, De Preter V, De Brandt E, Verbeke K, Swings J, et al.:Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol 72, 5990–5997, 2006.
29. Matsuki T, Watanabe K, Fujimoto J, Kado Y, Takada T, et al.:Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol 70, 167–173, 2004.
30. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, et al.:Effect of inulin on the human gut microbiota:stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 101, 541–550, 2009.
31. Wang RF, Cao WW, and Cerniglia CE, :PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Appl Environ Microbiol 62, 1242–1247, 1996.
32. Penders J, Vink C, Driessen C, London N, Thijs C, et al.:Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett 243, 141–147, 2005.
33. Goedert JJ, Jones G, Hua X, Xu X, Yu G, et al.:Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women:a population-based case-control pilot study. J Natl Cancer Inst 107(8), 1–5, 2015.
34. Dufour P, Schraub S, and Bergerat JP, :Cancer du sein. Guide pratique Cancérologie; Paris, Heures de France, 2009, pp. 4–13.
35. Charles MA, Eschwège E, and Basdevant A, :Monitoring the obesity epidemic in France:The obepi surveys 1997–2006. Obesity 16, 2182–2186, 2008.
36. Postollec F, Falentin H, Pavan S, Combrisson J, and Sohier D, :Recent advances in quantitative PCR (qPCR) applications in food microbiology. Food Microbiol 28(5), 848–861, 2011.
37. Coudeyras S, and Forestier C, :Microbiote et probiotiques:impact en sante humaine. Can J Microbiol 56, 611–650, 2010.
38. Dominianni C, Sinha R, Goedert JJ, Pei Z, Yang L, et al.:Sex, body mass index, and dietary fiber intake influence the human gut microbiome. PLoS One 10(4), 1–14, 2015. doi:10.1371/journal.pone.0124599.
39. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al.:An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031, 2006.
40. Ley RE, Backhed F, Turnbaugh PJ, Lozupone CA, Knight RD, et al.:Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102, 11070–11075, 2005.
41. Ley RE, Turnbaugh PJ, Klein S, and Gordon JI, :Microbial ecology:Human gut microbes associated with obesity. Nature 444, 1022–1023, 2006.
42. Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, et al.:Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 32, 1720–1724, 2008.
43. Zhang H, Dibaise JK, Zuccolo A, Kudrna D, Braidotti M, et al.:Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 106, 2365–2370, 2009.
44. Li M, Wang B, Zhang M, Rantalainen M, Wang S, et al.:Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 105, 2117–2122, 2008.
45. Louis P, and Flint HJ, :Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294, 1–8, 2009.
46. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, and Garcia-Gil LJ, :Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 12(12), 1136–1145, 2006.
47. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, et al.:Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105(43), 16731–16736, 2008.
48. Vinoloa AR, Rodriguesa HG, Hatanaka E, Satoa FT, Sampaio SC, et al.:Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 22, 849–855, 2011.
49. Park JS, Lee EJ, Lee JC, Kim WK, and Kim HS, :Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells:Involvement of NF-κB and ERK signaling pathways. Int Immunopharmacol 7(1), 70–77, 2007.
50. Faloia E, Michetti G, De Robertis M, Luconi MP, Furlani G, et al.:Inflammation as a Link between Obesity and Metabolic Syndrome. J Nutr Metab 2012, 7pp., 2012.
51. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, et al.:Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517, 2009.
52. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, et al.:Review article:the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104–119, 2007.
53. Lawless MW, Norris S, O'Byrne KJ, and Gray SG, :Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. Endocr Metab Immune Disord Drug Targets 9, 84–107, 2009.
54. Martin F, Peltonen J, Laatikainen T, Pulkkinen M, and Adlercreutz H, :Excretion of progesterone metabolites and estriol in faeces from pregnant women during ampicillin administration. J Steroid Biochem 6, 1339–1346, 1975.
55. Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, et al.:Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites:a cross-sectional study. J Transl Med 10, 253, 2012.
56. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, et al.:Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97, 755–765, 2005.
57. Woolcott CG, Shvetsov YB, Stanczy FZ, Wilkens LR, White KK, et al.:Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women:the Multiethnic Cohort Study. Endocr Relat Cancer 17, 125–134, 2010.
58. Hildebrandt MA, Hoffman C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, et al.:High fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1716–1724, 2009.
59. Adlercreutz H, :Western diet and Western diseases:Some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 201, 3–23, 1990.
60. Clavel T, Henderson G, Engst W, Doré J, and Blaut M, :Phylogeny of human intestinal bacteria that activate the dietary lignan secoisolariciresinol diglucoside. FEMS Microbiol Ecol 55, 471–478, 2006.
61. Mueller SO, Simon S, Chae K, Metzler M, and Korach KS, :Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol Sci 80, 14–25, 2004.
62. Cosentino M, Marino F, Ferrari M, Rasini E, Bombelli R, et al.:Estrogenic activity of 7-hydroxymatairesinol potassium acetate (HMR/lignanTM) from Norway spruce (Picea abies) knots and of its active metabolite enterolactone in MCF-7 cells. Pharmacol Res 56, 140–147, 2007.
63. Carreau C, Flouriot G, Bennetau-Pelissero C, and Potier M, :Enterodiol and enterolactone, two major diet-derived polyphenol metabolites have different impact on ER transcriptional activation in human breast cancer cells. J Steroid Biochem Mol Biol 110, 176–185, 2008.